Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Clovis Oncology to Announce Fourth Quarter/Year End 2012 Financial Results and Host Webcast Conference Call on February 28



  Clovis Oncology to Announce Fourth Quarter/Year End 2012 Financial Results
  and Host Webcast Conference Call on February 28

Business Wire

BOULDER, Colo. -- February 14, 2013

Clovis Oncology, Inc. (NASDAQ:CLVS) will announce its fourth quarter/year end
2012 financial results on Thursday, February 28, 2013, after the close of the
U.S. financial markets. Clovis’ senior management will host a conference call
and live audio webcast on Thursday, February 28, at 4:30 p.m. ET to discuss
the company’s results in greater detail.

The conference call is being webcast and can be accessed from the Clovis
Oncology website at www.clovisoncology.com. A replay of the webcast will be
available for 30 days.

About Clovis Oncology

Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring,
developing and commercializing innovative anti-cancer agents in the U.S.,
Europe and additional international markets. Clovis Oncology targets
development programs at specific subsets of cancer populations, and
simultaneously develops diagnostic tools that direct a compound in development
to the population that is most likely to benefit from its use. Clovis Oncology
is headquartered in Boulder, Colorado, and has additional offices in San
Francisco, California, and Cambridge, UK.

Contact:

Clovis Oncology, Inc.
Anna Sussman, 303-625-5022
asussman@clovisoncology.com
Breanna Burkart, 303-625-5023
bburkart@clovisoncology.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement